Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.
Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.
The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.
Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.
Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.
This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced significant executive appointments aimed at advancing its commercialization efforts in psoriasis and liver cancer. Dr. Pnina Fishman has been appointed as Executive Chairman of the Board, maintaining her role as Chief Scientific Officer. Motti Farbstein, who has been with the company for 20 years, will take over as Chief Executive Officer while continuing his duties as Chief Financial Officer. These changes will be effective from June 30, 2023. The company is pushing forward with two pivotal Phase III trials for its drug candidates, Piclidenoson for psoriasis and Namodenoson for liver cancer. Can-Fite's prospects in the market are substantial, with ongoing evaluations and regulatory designations for its drugs, aimed at addressing major health conditions and tapping into multi-billion dollar markets.
Can-Fite BioPharma (NYSE American: CANF) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its registration plan for a pivotal Phase III clinical trial targeting moderate to severe psoriasis. The trial will evaluate the safety and efficacy of Piclidenoson, the company's lead drug candidate. This follows the recent successful topline results from the Phase III COMFORT™ study, which demonstrated significant improvement over placebo. Can-Fite is also preparing a comparable data package for the US FDA. The CEO emphasized the drug's oral dosage, safety profile, and potential in a large market for effective psoriasis treatments.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?
What does Can-Fite BioPharma Ltd. specialize in?
Where is Can-Fite BioPharma Ltd. located?
What is Piclidenoson?
What is Namodenoson used for?
What stage are the trials for Namodenoson?
What is the A3 adenosine receptor (A3AR)?
How does Can-Fite BioPharma's technology benefit patients?
What is the significance of Can-Fite BioPharma's partnerships?
Is Can-Fite BioPharma listed on any stock exchange?
What is the focus of Can-Fite BioPharma's current projects?
